Why Is Immunic Stock Soaring Friday?

Immunic Inc. (NASDAQ:IMUX) stock is surging on Friday with a robust session volume of 55.97 million compared to the average volume of 1.62 million, according to Benzinga Pro data.

The surge follows the announcement of an oversubscribed private placement aimed at raising up to $400 million to accelerate its transformation into a commercial-stage company.

Equity Raise

The company announced a private placement of 229.08 million pre-funded warrants at $0.873 per pre-funded warrant, for upfront gross proceeds of $200 million.

In addition, the company will issue warrants to purchase up to an aggregate of 229.076 million shares at an exercise price of $0.873 per share, for up to an additional $200 million in gross proceeds.

The funding is expected to support the completion of the Phase 3 ENSURE trial in relapsing multiple sclerosis, with topline data expected by the end of 2026.

Immunic plans to submit a New Drug Application (NDA) in the U.S. in mid-2027, with a targeted potential regulatory approval date in 2028.

Immunic is working towards initiation of a phase 3 clinical program in primary progressive multiple sclerosis, which is expected later this year and estimated to take approximately 3.5 to 4 years to complete.

Management Transition

In addition to the funding details, Immunic has made significant leadership changes, elevating Simona Skerjanec to interim Chairperson of the Board and initiating a search for a new CEO with commercial expertise.

Immunic’s Co-Founder and CEO, Daniel Vitt, plans to transition to a new senior executive role focused on strengthening the company’s scientific strategy.

Technical Analysis

Immunic’s stock is currently trading 63.2% above its 20-day simple moving average (SMA) and 50.5% above its 100-day SMA, indicating strong short-term momentum. Over the past 12 months, shares have increased by 14.46% and are positioned closer to their 52-week highs than lows, suggesting a bullish trend.

The RSI is at 69.12, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of a neutral RSI and bullish MACD suggests mixed momentum, indicating potential for continued upward movement.

• Key Resistance: $1.50
• Key Support: $1.00

Sector Performance

Immunic is outperforming its sector significantly, with a daily gain of 24.12% compared to the Healthcare sector’s 1.54% increase. This strong performance places Immunic as a leading player in a sector that has shown modest growth over the past 30 days, where the sector has only gained 0.32%.

The Healthcare sector is currently ranked second among all sectors, indicating a favorable environment for stocks within this space. Over the past 90 days, the sector has seen a 4.40% increase, suggesting a positive trend that could benefit Immunic as it transitions to a commercial-stage company.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating. Recent analyst moves include:

• D. Boral Capital: Buy (Lowers Target to $4)
• HC Wainwright & Co.: Buy (Maintains Target to $8)
• D. Boral Capital: Buy (Maintains Target to $8)

IMUX Price Action: Immunic shares were up 23.56% at $1.07 at the time of publication on Friday, according to Benzinga Pro data.

Photo by PeopleImages.com – Yuri A via Shutterstock